Recommended Approach to Eosinophilia of 15.3%
A patient with 15.3% eosinophils requires immediate calculation of the absolute eosinophil count (AEC), followed by a systematic evaluation to identify the underlying cause and assess for end-organ damage, with the diagnostic pathway determined by whether the AEC indicates mild, moderate, or severe eosinophilia.
Initial Step: Calculate Absolute Eosinophil Count
The percentage alone is insufficient—you must calculate the AEC by multiplying 15.3% by the total white blood cell count 1. This determines the severity category:
- Mild eosinophilia: 500-1,499 cells/μL
- Moderate eosinophilia: 1,500-4,999 cells/μL
- Severe/hypereosinophilia: ≥5,000 cells/μL
Critical distinction: Hypereosinophilia (≥1,500 cells/μL) is rarely explained by allergy alone and always warrants comprehensive workup 1.
Focused History and Physical Examination
Key Historical Elements to Elicit:
Travel and exposure history 2:
- Recent travel to endemic regions (Africa, Asia, Latin America) for parasitic infections
- Freshwater swimming exposure 2-8 weeks prior (schistosomiasis presents with fever, cough, urticarial rash, and marked eosinophilia often >5,000 cells/μL)
- Exclude Loa loa exposure before any ivermectin treatment
Medication review:
- New medications coinciding with eosinophilia onset
- Drug reactions are a common secondary cause 3
Symptoms suggesting end-organ involvement 4, 5:
- Cardiac: Chest pain, dyspnea, heart failure symptoms (life-threatening complication)
- Pulmonary: Refractory asthma, need for prolonged/recurrent corticosteroids, decreasing efficacy of asthma therapy
- Dermatologic: Urticaria, rash, angioedema
- Gastrointestinal: Diarrhea, abdominal pain, dysphagia
- Neurologic: Peripheral neuropathy, encephalopathy
- Constitutional: Fever, weight loss, night sweats
Atopic disease history:
- Asthma, allergic rhinitis, atopic dermatitis (most common causes, accounting for 53.4% of cases) 6
Red Flags Requiring Urgent Specialist Referral 5:
- AEC ≥1,000 cells/μL with persistent elevation
- Multiorgan system involvement
- Refractory asthma requiring prolonged corticosteroids
- Extra-pulmonary findings with eosinophilia
- Evolving/worsening symptoms over weeks to months
Diagnostic Testing Algorithm
First-Tier Testing (All Patients):
Laboratory evaluation:
- Complete metabolic panel, liver function tests (assess organ involvement)
- Troponin, BNP (cardiac damage screening)
- IgE level
- Stool microscopy × 3 concentrated samples for ova and parasites 2
- HIV testing
- Vitamin B12 level
Imaging:
- Chest radiograph (infiltrates, nodules in Loeffler's syndrome or chronic eosinophilic pneumonia)
- Echocardiogram if AEC >1,500 cells/μL or any cardiac symptoms (assess for endomyocardial involvement)
Second-Tier Testing (Based on Clinical Suspicion):
For travel history to endemic regions 2:
- Schistosomiasis serology (if freshwater exposure in Africa 2-8 weeks prior—serology and stool may be negative early, but empirical treatment justified)
- Strongyloides serology (critical to exclude before corticosteroid use—risk of hyperinfection)
- Filariasis serology (pan-filarial antibody ELISA)
- Toxocara serology
- Faecal PCR for helminths
For suspected primary eosinophilia or HES:
- Peripheral blood flow cytometry (aberrant T-cell populations)
- Serum tryptase (systemic mastocytosis)
- Molecular testing: FIP1L1-PDGFRA, PDGFRB, FGFR1 mutations (myeloid variant HES—responsive to tyrosine kinase inhibitors) 6
- Bone marrow biopsy with cytogenetics if primary disorder suspected
For specific organ involvement:
- Pulmonary: CT chest, pulmonary function tests, Aspergillus IgE and precipitins (ABPA occurs in 11.6% of cases) 6
- Cardiac: Cardiac MRI if echocardiogram abnormal or troponin elevated
- Gastrointestinal: Endoscopy with biopsies if dysphagia or GI symptoms
- Dermatologic: Skin biopsy of rash
- ANCA testing if vasculitis suspected (EGPA occurs in 1.7% of cases) 6
Treatment Approach
Empirical Treatment for Asymptomatic Eosinophilia with Travel History
If negative initial stool microscopy but travel to endemic regions 2:
- Albendazole 400 mg PO single dose PLUS
- Ivermectin 200 μg/kg PO single dose (treats prepatent geohelminth infections)
- CRITICAL: Exclude Loa loa before ivermectin (risk of encephalopathy)
For suspected acute schistosomiasis (fever, rash, cough 2-8 weeks post-freshwater exposure) 2:
- Praziquantel 25 mg/kg PO three times daily for 2-3 days
- Repeat treatment at 8 weeks (eggs and immature schistosomulae are treatment-resistant)
- Consider corticosteroids (prednisolone 30 mg daily for 5 days) for Loeffler's syndrome symptoms 2
Targeted Treatment Based on Diagnosis
Secondary eosinophilia: Treat underlying condition 3
- Discontinue offending medications
- Optimize asthma/atopic disease management
- Complete antiparasitic therapy as indicated
Primary eosinophilia/HES with FIP1L1-PDGFRA mutation:
- Tyrosine kinase inhibitors (imatinib)—requires hematology consultation
EGPA:
- Immunosuppression with corticosteroids ± cyclophosphamide or rituximab
- Anti-IL-5 biologics (mepolizumab, benralizumab) 4
Idiopathic HES with end-organ damage:
- Corticosteroids as first-line
- Consider anti-IL-5 biologics if corticosteroid-dependent 4
Common Pitfalls to Avoid
- Never use percentage alone—always calculate AEC 1
- Never give ivermectin without excluding Loa loa in patients with Central/West African travel 2
- Never start corticosteroids before excluding Strongyloides—risk of fatal hyperinfection 2
- Never assume allergy alone if AEC ≥1,500 cells/μL—requires full workup 1
- Never delay cardiac evaluation if hypereosinophilia present—cardiac involvement is life-threatening 4
- Etiology remains undetermined in 19.8% of cases—close monitoring required even without definitive diagnosis 6
When to Refer
Immediate specialist referral indicated for 5:
- AEC ≥1,500 cells/μL without clear secondary cause
- Any evidence of end-organ damage
- Suspected HES, EGPA, or systemic mastocytosis
- Refractory symptoms despite treatment of presumed cause
- Need for immunosuppressive therapy or biologics